Identification of a Novel, Oncogenic and Targetable <i>TPR::ABL2</i> Fusion Gene in T‐Cell Acute Lymphoblastic Leukaemia
<i>ABL2</i> rearrangements represent a subtype of acute lymphoblastic leukaemia (ALL) associated with poor prognosis and survival. This study reports a high-risk T-cell ALL (T-ALL) case with a novel TPR::ABL2 gene fusion resulting from a chromosomal deletion. Overexpression of <i>TPR::ABL2</i> in Ba/F3 cells promoted cytokine-independent growth, demonstrating its oncogenic nature. Both primary patient and Ba/F3 cells carrying <i>TPR::ABL2</i> exhibited kinase activation and sensitivity to tyrosine kinase inhibitors (TKIs). This study expands the repertoire of <i>ABL2</i> fusions identified in ALL and supports the incorporation of TKIs into T-ALL treatment regimens to improve outcomes for this subtype.
Authors
- Morag Whyte
- Susan L. Heatley (ORCID: https://orcid.org/0000-0001-7497-6477)
- Jacqueline Rehn (ORCID: https://orcid.org/0000-0001-5043-6943)
- Elias Lagonik (ORCID: https://orcid.org/0000-0002-8393-4081)
- Laura N Eadie (ORCID: https://orcid.org/0000-0003-1912-7602)
- Deborah L. White (ORCID: https://orcid.org/0000-0003-4844-333X)
- Elyse C. Page (ORCID: https://orcid.org/0000-0002-8990-2574)
- Caitlin E Schutz
- Muirin Healy
- Timothy P. Hughes
- Andrew S. Moore
- David T. Yeung
Institutions
- Royal Adelaide Hospital (AU)
- Mackay Base Hospital (AU)
- Children’s Health Queensland Hospital and Health Service (AU)
- ANZCHOG (AU)
- South Australian Health and Medical Research Institute (AU)
- Children's Health Queensland Hospital and Health Service (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- eJHaem
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1002/jha2.70255
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Australian Cancer Research Foundation
- Medical Research Council
- National Health and Medical Research Council
- Cancer Council South Australia